Banner

Biotin Improves HER2+ Status Test Accuracy for Breast Cancer Patients

Banner

The tests that were being used to identify HER-2 status in advanced breast cancer patients who could potentially respond to Herceptin ® treatment were both unreliable and inaccurate. Since studies have shown Herceptin® combined with chemotherapy increases both response and survival rates in these HER-2+ breast cancer patients, it was obviously important to find a way to improve these tests.32

Banner

Researchers used the avidin/biotin system to help overcome the difficulty. Biotinylated Herceptin® was able to accurately detect patients with HER-2 amplified tumors. It was also discovered to be a predictor of clinical outcome, since those that it did detect were likely to benefit from Herceptin® treatment. This was because the researchers were able to evaluate the availability of trastuzumab-binding sites on individual tumors.32

Disclaimer: This website is not intended to replace professional consultation, diagnosis, or treatment by a licensed physician. If you require any medical related advice, contact your physician promptly. Information at Biotin.com is exclusively of a general reference nature. Do not disregard medical advice or delay treatment as a result of accessing information at this site.
Trastuzumab.32
A protein in egg whites.9
Attached to a biotin molecule.9
 
 
 
Protected by Copyscape Online Copyright Search